Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDK9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDK9/Cyclin T1 Active Complex Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Sf9 insect cell co-expressed to preserve native phosphorylation states. |
View CDK9 Products |
| Gene Delivery | CDK9 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and target engagement assays. |
View CDK9 Products |
| Benchmark Ab | Anti-CDK9 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View CDK9 Products |
| Validator | CDK9 siRNA Set For target knockdown verification and target specificity validation. |
View CDK9 Products |
| Related Target A | CCNT1 (Cyclin T1) Essential regulatory subunit that forms the active P-TEFb complex with CDK9. |
View CCNT1 Products |
| Related Target B | CDK2 Critical off-target homolog. Selectivity screening against CDK2 is essential to avoid clinical myelosuppression. |
View CDK2 Products |
| Related Target C | CDK7 Upstream CAK subunit. Counter-screening ensures selective transcriptional inhibition. |
View CDK7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity Profiling | Full CDK Family Homolog Panel (CDK1, CDK2, CDK5, CDK7, CDK12) available with >95% purity verified by SDS-PAGE. |
| Reconstitution of Active Complex | Co-expressed CDK9/Cyclin T1 (CCNT1) heterodimer complex, sequence verified with theoretical MW confirmation. |
| Lack of Controls | Clinical Benchmark Recombinant Antibodies included for target engagement comparison. |
| False Positives in Screening | Validated siRNA sets included for orthogonal target knockdown and specificity checks. |
Live CDK9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDK9 therapeutics is intensifying, with major players shifting focus from traditional pan-CDK inhibitors to highly selective small molecule inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting transcription-addicted cancers (e.g., AML, Myc-driven solid tumors) while minimizing systemic toxicities associated with off-target CDK family inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Highly Selective Small Molecule | AstraZeneca, Vincerx Pharma, Kronos Bio | Acute Myeloid Leukemia (AML), Lymphoma, Solid Tumors | Kinase Selectivity Assay (Need CDK9/Cyclin T1 complex vs. CDK family panel) |
| PROTAC / Degraders | Fosun Pharma, Nurix Therapeutics | Hematological Malignancies | Ubiquitination & Degradation Assay (Need pure CDK9 protein and stable cell lines) |
| Combination Therapies | Academic & Clinical Consortia | Refractory Solid Tumors | Synergy Validation (Need validated knockdown siRNA and benchmark antibodies) |